

## Special Issue

# Oncology: State-of-the-Art Research in UK, 2nd Edition

### Message from the Guest Editors

Among many other countries, the UK is at the forefront of cancer research. There are commitments from stakeholders from academic institutions, health service organisations, industries, funding bodies and public and patient advocacy groups to support the research of all types of cancer. We have a unique National Health Service, which emphasises the needs of everyone and is free at the point of delivery. It believes that integrating research into the health service organisation will improve outcomes and transform cancer care.

In this Special Issue, we aim to showcase state-of-the-art research in oncology in the UK. We invite submissions looking at all kinds of research covering all cancer types and stages, from basic laboratory research to translational and clinical research, including cohort studies, randomised controlled trials and epidemiological studies. Narrated reviews describing the history and significant contributions of cancer research in the UK are also welcome.

---

### Guest Editors

Prof. Dr. Kwok-Leung Cheung

School of Medicine, University of Nottingham, Derby DE22 3DT, UK

Dr. Ruth Parks

School of Medicine, University of Nottingham, Derby DE22 3DT, UK

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/190506](https://mdpi.com/si/190506)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)